Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease
Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease
复制标题
DOI：
10.1161/atvbaha.119.311994
复制
发表时间：
2019-07-01
影响因子：
8.7
通讯作者：
Swirski, Filip K.
中科院分区：
文献类型：
--
作者：
Mindur, John E.;Swirski, Filip K.
生长因子，如csf（集落刺激因子），EGFs（表皮生长因子）和FGFs（成纤维细胞生长因子），是控制广泛细胞功能的信号蛋白。尽管生长因子网络对细胞间通讯和组织稳态至关重要，但它们的异常产生或调节发生在各种病理中。靶向生长因子或其受体的临床策略用于治疗各种疾病，但尚未用于心血管疾病。在这篇综述中，我们主要关注M-CSF（巨噬细胞- csf）、GM-CSF（粒细胞-M-CSF）、IL（白细胞介素）-3、EGFR（表皮生长因子受体）和FGF21（成纤维细胞生长因子21）。我们首先讨论靶向这些生长因子在其他疾病背景下（即炎症/自身免疫性疾病、癌症或代谢紊乱）的疗效，然后考虑支持或反对靶向它们治疗心血管疾病的论点。
Growth factors, such as CSFs (colony-stimulating factors), EGFs (epidermal growth factors), and FGFs (fibroblast growth factors), are signaling proteins that control a wide range of cellular functions. Although growth factor networks are critical for intercellular communication and tissue homeostasis, their abnormal production or regulation occurs in various pathologies. Clinical strategies that target growth factors or their receptors are used to treat a variety of conditions but have yet to be adopted for cardiovascular disease. In this review, we focus on M-CSF (macrophage-CSF), GM-CSF (granulocyte-M-CSF), IL (interleukin)-3, EGFR (epidermal growth factor receptor), and FGF21 (fibroblast growth factor 21). We first discuss the efficacy of targeting these growth factors in other disease contexts (ie, inflammatory/autoimmune diseases, cancer, or metabolic disorders) and then consider arguments for or against targeting them to treat cardiovascular disease.